Zomedica Corp. (NYSE American:ZOM) announced today that Larry Heaton, Zomedica's Chief Executive Officer, is scheduled to provide a company overview and its prospects for growth at the Dawson James Securities Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.
To access the live webcast for the presentation on October 12th, please visit https://wsw.com/webcast/dawson7/zom/1894626 or check Zomedica's website after the conference at https://investors.zomedica.com/events-presentations for an archived copy. To register for the conference and participate in 1on1 meetings please visit Dawson James Small Cap Growth Conference.
About Dawson James Securities
Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL. http://www.dawsonjames.com.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Investor Relations Contact:
PCG Advisory Group
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.646.823.8656
Last Trade: | US$0.12 |
Daily Volume: | 12,083,028 |
Market Cap: | US$117.590M |
November 27, 2024 November 14, 2024 November 08, 2024 November 07, 2024 October 24, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB